Arlington, MA – According to filings with the U.S. Securities and Exchange Commission, Revere Pharmaceuticals is raising $3,454,842.00 in new funding. Sources indicate as part of senior management President, Robert Silverman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Revere Pharmaceuticals

Revere Pharmaceuticals is a Boston-based startup leading the way in the development of new cancer treatments targeting Rac1 GTPase, an important target in the progression of different cancers. R-ketorolac, our lead candidate, is a first-in-class Rac1 inhibitor that shows both clinical and non-clinical evidence of efficacy in ovarian cancer. Rac1 activity is a key driver of metastatic progression and drug resistance in diverse cancer types. Revere’s lead Rac1 targeted drug candidate is REV-440. Successful development of REV-440 has the potential to provide meaningful clinical impact in multiple refractory cancers characterized by aberrant Rac1 signaling.

To learn more about Revere Pharmaceuticals, visit http://www.reverepharma.com/

Contact:
Robert Silverman, President
781-718-9033
https://www.linkedin.com/in/robert-silverman-467b236/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved